Citations

Clear

3942 citation(s) found for "To, Van".

Immobilization of vitronectin‐binding heparan sulfates onto surfaces to support human pluripotent stem cells
Yap, Lynn , Murali, Sadasivam, Bhakta, Gajadhar, Chen, Allen Kuan‐Liang, Sim, Lyn Chiin, Lim, Yu Ming , Goh, James Cho‐Hong , Oh, Steve , Choo, Andre , Wijnen, André J. van , Robinson, David E., Whittle, Jason D. , Short, Robert D. , Nurcombe, Victor , Cool, Simon M. , van Wijnen, Andre J , Titmarsh, Drew M. , Bardor, Muriel , Birch, William R.

Mayo Clinic

Journal of Biomedical Materials Research Part B: Applied Biomaterials | September 20, 2017 | Volume: 106 | Issue: 5 | Pages: 1887-1896

10.1002/jbm.b.33999 | PMID 28941021 Get It

AbstractFunctionalizing medical devices with polypeptides to enhance their performance has become important for improved clinical success. The extracellular matrix (ECM) adhesion protein vitronectin (VN) is an effective coating, although the chemistry used to attach VN often reduces its bioactivity. In vivo, VN binds the ECM in a sequence‐dependent manner with heparan sulfate (HS) glycosaminoglycans. We reasoned therefore that sequence‐based affinity chromatography could be used to isolate a VN‐binding HS fraction (HS9) for use as a coating material to capture VN onto implant surfaces. Binding avidity and specificity of HS9 were confirmed by enzyme‐linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR)‐based assays. Plasma polymerization of allylamine (AA) to tissue culture‐treated polystyrene (TCPS) was then used to capture and present HS9 as determined by radiolabeling and ELISA. HS9‐coated TCPS avidly bound VN, and this layered surface supported the robust attachment, expansion, and maintenance of human pluripotent stem cells. Compositional analysis demonstrated that 6‐O‐ and N‐sulfation, as well as lengths greater than three disaccharide units (dp6) are critical for VN binding to HS‐coated surfaces. Importantly, HS9 coating reduced the threshold concentration of VN required to create an optimally bioactive surface for pluripotent stem cells. We conclude that affinity‐purified heparan sugars are able to coat materials to efficiently bind adhesive factors for biomedical applications. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 1887–1896, 2018.
Animal models for studying the etiology and treatment of low back pain
Shi, Changgui , Qiu, Sujun , Riester, Scott M. , Das, Vaskar, Zhu, Bingqian , Wallace, Atiyayein A., Wijnen, André J. van , Mwale, Fackson , Iatridis, James C. , Sakai, Daisuke , Votta‐Velis, Gina , Yuan, Wen, Im, Hee‐Jeong , van Wijnen, Andre J , Iatridis, James C , Yuan, Wen

Mayo Clinic

Journal of Orthopaedic Research | September 18, 2017 | Volume: 36 | Issue: 5 | Pages: 1305-1312

10.1002/jor.23741 | PMID 28921656 Get It

ABSTRACTChronic low back pain is a major cause of disability and health care costs. Effective treatments are inadequate for many patients. Animal models are essential to further understanding of the pain mechanism and testing potential therapies. Currently, a number of preclinical models have been developed attempting to mimic aspects of clinical conditions that contribute to low back pain (LBP). This review focused on describing these animal models and the main behavioral tests for assessing pain in each model. Animal models of LBP can be divided into the following five categories: Discogenic LBP, radicular back pain, facet joint osteoarthritis back pain, muscle‐induced LBP, and spontaneous occurring LBP models. These models are important not only for enhancing our knowledge of how LBP is generated, but also for the development of novel therapeutic regimens to treat LBP in patients. © 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 36:1305–1312, 2018.
LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression
Liang, Yi , Ahmed, Musaddeque , Guo, Haiyang , Soares, Fraser , Hua, Junjie T. , Gao, Shuai , Lu, Catherine , Poon, Christine , Han, Wanting , Langstein, Jens , Ekram, Muhammad B. , Takhar, Mandeep, Erho, Nicholas , Karnes, R. Jeffrey , Chadwick, Dianne, Boutros, Paul C. , Arrowsmith, C.H. , Feng, Felix Y. , Joshua, Anthony M. , Zoubeidi, Amina , Cai, Changmeng , He, Housheng Hansen , Boutros, Paul C , He, Housheng Hansen , Ahmed, Musaddeque , Li, Brian , Davicioni, Elai , Kwast, Theodorus van der

Mayo Clinic

Cancer Research | September 15, 2017 | Volume: 77 | Issue: 20 | Pages: 5479-5490

10.1158/0008-5472.can-17-0496 | PMID 28916652 Get It

Abstract Androgen receptor (AR) signaling is a key driver of prostate cancer, and androgen-deprivation therapy (ADT) is a standard treatment for patients with advanced and metastatic disease. However, patients receiving ADT eventually develop incurable castration-resistant prostate cancer (CRPC). Here, we report that the chromatin modifier LSD1, an important regulator of AR transcriptional activity, undergoes epigenetic reprogramming in CRPC. LSD1 reprogramming in this setting activated a subset of cell-cycle genes, including CENPE, a centromere binding protein and mitotic kinesin. CENPE was regulated by the co-binding of LSD1 and AR to its promoter, which was associated with loss of RB1 in CRPC. Notably, genetic deletion or pharmacological inhibition of CENPE significantly decreases tumor growth. Our findings show how LSD1-mediated epigenetic reprogramming drives CRPC, and they offer a mechanistic rationale for its therapeutic targeting in this disease. Cancer Res; 77(20); 5479–90. ©2017 AACR.
Trajectories of Glycemic Change in a National Cohort of Adults With Previously Controlled Type 2 Diabetes
Houten, Holly K. Van , Shah, Nilay D. , McCoy, Rozalina G. , Ngufor, Che , Caffo, Brian S.

Mayo Clinic

Medical Care | September 15, 2017 | Volume: 55 | Issue: 11 | Pages: 956-964

10.1097/mlr.0000000000000807 | PMID 28922296 Get It

Background: Individualized diabetes management would benefit from prospectively identifying well-controlled patients at risk of losing glycemic control. Objectives: To identify patterns of hemoglobin A1c (HbA1c) change among patients with stable controlled diabetes. Research Design: Cohort study using OptumLabs Data Warehouse, 2001–2013. We develop and apply a machine learning framework that uses a Bayesian estimation of the mixture of generalized linear mixed effect models to discover glycemic trajectories, and a random forest feature contribution method to identify patient characteristics predictive of their future glycemic trajectories. Subjects: The study cohort consisted of 27,005 US adults with type 2 diabetes, age 18 years and older, and stable index HbA1c <7.0%. Measures: HbA1c values during 24 months of observation. Results: We compared models with k=1, 2, 3, 4, 5 trajectories and baseline variables including patient age, sex, race/ethnicity, comorbidities, medications, and HbA1c. The k=3 model had the best fit, reflecting 3 distinct trajectories of glycemic change: (T1) rapidly deteriorating HbA1c among 302 (1.1%) youngest (mean, 55.2 y) patients with lowest mean baseline HbA1c, 6.05%; (T2) gradually deteriorating HbA1c among 902 (3.3%) patients (mean, 56.5 y) with highest mean baseline HbA1c, 6.53%; and (T3) stable glycemic control among 25,800 (95.5%) oldest (mean, 58.5 y) patients with mean baseline HbA1c 6.21%. After 24 months, HbA1c rose to 8.75% in T1 and 8.40% in T2, but remained stable at 6.56% in T3. Conclusions: Patients with controlled type 2 diabetes follow 3 distinct trajectories of glycemic control. This novel application of advanced analytic methods can facilitate individualized and population diabetes care by proactively identifying high risk patients.
Relating gastric scintigraphy and symptoms to motility capsule transit and pressure findings in suspected gastroparesis
Hasler, William L. , May, Kevin P. , Wilson, Laura , Natta, Mark L. Van , Parkman, Henry P. , Pasricha, Pankaj J. , Koch, Kenneth L. , Abell, Thomas L. , McCallum, Richard W. , Snape, William J., Sarosiek, Irene , Farrugia, Gianrico , Calles-Escandón, Jorge, Grover, Madhusudan , Tonascia, James , Lee, L. A., Miriel, Laura , Hamilton, Frank A., Hasler, W L , Parkman, H P , Abell, T L , Nguyen, Linda Anh B. , Clarke, John O.

Mayo Clinic

Neurogastroenterology & Motility | September 5, 2017 | Volume: 30 | Issue: 2 | Pages: No page available

10.1111/nmo.13196 | PMID 28872760 Get It

Abstract Background Wireless motility capsule ( WMC ) findings are incompletely defined in suspected gastroparesis. We aimed to characterize regional WMC transit and contractility in relation to scintigraphy, etiology, and symptoms in patients undergoing gastric emptying testing. Methods A total of 209 patients with gastroparesis symptoms at NIDDK Gastroparesis Consortium centers underwent gastric scintigraphy and WMC s on separate days to measure regional transit and contractility. Validated questionnaires quantified symptoms. Key Results Solid scintigraphy and liquid scintigraphy were delayed in 68.8% and 34.8% of patients; WMC gastric emptying times ( GET ) were delayed in 40.3% and showed 52.8% agreement with scintigraphy; 15.5% and 33.5% had delayed small bowel ( SBTT ) and colon transit ( CTT ) times. Transit was delayed in ≥2 regions in 23.3%. Rapid transit was rarely observed. Diabetics had slower GET but more rapid SBTT versus idiopathics ( P ≤ .02). GET delays related to greater scintigraphic retention, slower SBTT , and fewer gastric contractions ( P ≤ .04). Overall gastroparesis symptoms and nausea/vomiting, early satiety/fullness, bloating/distention, and upper abdominal pain subscores showed no relation to WMC transit. Upper and lower abdominal pain scores ( P ≤ .03) were greater with increased colon contractions. Constipation correlated with slower CTT and higher colon contractions ( P = .03). Diarrhea scores were higher with delayed SBTT and CTT ( P ≤ .04). Conclusions & Inferences Wireless motility capsules define gastric emptying delays similar but not identical to scintigraphy that are more severe in diabetics and relate to reduced gastric contractility. Extragastric transit delays occur in >40% with suspected gastroparesis. Gastroparesis symptoms show little association with WMC profiles, although lower symptoms relate to small bowel or colon abnormalities.
Esthesioneuroblastoma and Olfactory Preservation: Is it Reasonable to Attempt Smell Preservation?
Janus, Jeffrey R. , Hughes, Joshua , Stokken, Janalee K., Moore, Eric J. , Ryan, Tarek, Link, Michael J. , Hughes, Joshua D, Gompel, Jamie J. Van , Price, Daniel L.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | August 28, 2017 | Volume: 79 | Issue: 02 | Pages: 184-188

10.1055/s-0037-1606307 | PMID 29868325 Get It

Objective Olfactory preservation after resection of esthesioneuroblastoma (ENB) has been reported, however, the ability to predict tumor involvement of the olfactory system is critical to this surgical strategy. This study aims to answer the question: Can a surgeon predict, based on preoperative imaging, whether there is unilateral involvement of the olfactory system allowing for safe attempt of olfactory preservation? Methods This is a retrospective review of post-resection ENB meeting inclusion criteria of having bilateral olfactory tracts and bulbs submitted at the time of primary resection for pathologic margins. Five board-certified skull base surgeons blinded to the pathology individually reviewed the preoperative MRI scans to predict degree of tumor involvement. Results Olfactory bulb involvement occurred in both bulbs in 35% of cases and unilateral in 39% of cases, and there was no involvement in 26% of cases sampled. When comparing physician prediction of involved tracts or bulbs, involvement was appropriate or over-called (i.e., called positive when pathology was in fact negative) in 96% of cases. Conclusion This study demonstrates unilateral or no pathologic olfactory involvement of the olfactory system in 65% of cases. Our ability to predict this involvement, which may allow for a management strategy that attempts to preserve olfactory function, was accurate at 96%. Therefore, interpretation of imaging and proceeding with smell preservation in ENB appears reasonable in this cohort.Level of Evidence: Level 2b.
Flow Cytometric Immune Profiling in Infliximab-Associated Tuberculosis
Pennington, Kelly M. , Sasieta, Humberto C., Ramos, Guiherme P, Erskine, Courtney L. , Keulen, Virginia P. Van , Peikert, Tobias, Escalante, Patricio , Ramos, Guilherme Piovezani , Van Keulen, Virginia P, Ramos, Guilherme P

Mayo Clinic

Clinical Medicine Insights: Case Reports | August 24, 2017 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/1179547617724776 | PMID 28890660 Get It

Tumor necrosis factor α antagonists are increasingly used to treat inflammatory and autoimmune disorders and are associated with increased risk of active tuberculosis. Diagnosis of active tuberculosis in patients taking tumor necrosis factor α antagonists can be challenging owing to increased incidence of extrapulmonary manifestations and false-negative results on current available diagnostic tests. We present a case of a young woman on infliximab for ulcerative colitis who presented with disseminated tuberculosis. As part of a research study, we performed flow cytometric immune profiling, which has previously not been reported in patients with active tuberculosis taking tumor necrosis α antagonists. The flow cytometry results were within the positive thresholds for tuberculosis infection. Flow cytometric immune profiling may be a valid diagnostic tool for patients taking tumor necrosis factor α antagonists.
Expanded phenotype in a patient with spastic paraplegia 7
Gass, Jennifer , Blackburn, Patrick R. , Jackson, Jessica L. , Macklin, Sarah , Gerpen, Jay Van, Atwal, Paldeep S. , Jackson, Jessica, Van Gerpen, Jay, Atwal, Paldeep S , Gerpen, Jay A. van

Mayo Clinic

Clinical Case Reports | August 24, 2017 | Volume: 5 | Issue: 10 | Pages: 1620-1622

10.1002/ccr3.1109 | PMID 29026558 Get It

Key Clinical MessageHereditary spastic paraplegia is a group of clinically and genetically heterogeneous neurodegenerative disorders, often characterized by weakness and spasticity in the lower limbs. In our study, we describe a spastic paraplegia type 7 patient with an expanded phenotype who was diagnosed after the discovery of pathogenic variants in SPG7.
Volumetric analysis of olfactory neuroblastoma skull base laterality and implications on neck disease
Marinelli, John P. , Link, Michael J., Moore, Eric J. , Lees, Katherine A. , Kaczor, Mark W., Janus, Jeffrey R. , Gompel, Jamie J. Van , Price, Daniel L.

Mayo Clinic

The Laryngoscope | August 22, 2017 | Volume: 128 | Issue: 4 | Pages: 864-870

10.1002/lary.26843 | PMID 28833165 Get It

ObjectiveTo determine if the laterality of primary tumors in patients with olfactory neuroblastoma (ONB) influenced the pattern and development of neck disease.MethodsUsing a retrospective cohort study design from 1994 to 2015, the primary tumors of patients who either presented with or developed neck disease were volumetrically analyzed using iPlan software (version 3.0.0, BrainLAB, Feldkirchen, Germany) by two independent observers. Agreement of volume‐derived sidedness was assessed with a kappa statistic, whereas agreement in volume‐derived degree of tumor laterality was evaluated with an intraclass correlation coefficient. A one‐sample t test was used to assess the difference in dominant percentage between the two observers.ResultsSixty‐one patients with histological diagnosis and treatment of ONB at our institution were identified. Twenty‐four patients exhibited neck involvement, 13 of whom could be volumetrically analyzed. Tumors that were greater than 75% eccentric to one side all exhibited contralateral disease, whereas the majority of unilateral neck disease was associated with relatively midline masses. Within the entire cohort, ipsilateral level 2 lymph nodes displayed the highest involvement (83%, 20 of 24), followed by ipsilateral level 1 (54%, 13 of 24), contralateral level 2 (46%, 11 of 24), contralateral level 1 (21%, 5 of 24), and ipsilateral level 3 (21%, 5 of 24).ConclusionIpsilateral neck involvement frequently was observed; however, the degree of ONB primary site laterality did not appear to have implications on the development of contralateral neck disease. Therefore, when considering elective therapy to the neck, ONB laterality should not be used to justify unilateral neck treatment.Level of Evidence4. Laryngoscope, 128:864–870, 2018
Plausibility criteria for putative pathophysiological mechanisms in functional gastrointestinal disorders: a consensus of experts
Tack, Jan , Corsetti, Maura , Camilleri, Michael , Suzuki, Hidekazu , Talley, Nicholas J. , Törnblom, Hans , Oudenhove, Lukas Van , Corsetti, M , Tack, Jan , Quigley, Eamonn M.M. , Simrén, Magnus

Mayo Clinic

Gut | August 16, 2017 | Volume: 67 | Issue: 8 | Pages: 1425-1433

10.1136/gutjnl-2016-312230 | PMID 28814481 Get It

Background and aims The functional gastrointestinal disorders (FGIDs) are extremely common conditions associated with a considerable personal, social and health economic burden. Managing FGIDs in clinical practice is challenging because of the uncertainty of symptom-based diagnosis, the high frequency of overlap between these conditions and the limited efficacy of available therapies. It has often been argued that successful drug development and management of FGIDs requires knowledge of the underlying pathophysiology. Numerous and highly variable candidate pathophysiological mechanisms have been implicated in the generation of FGID symptoms, but there is no current consensus on how to best define the relevance of these disturbances. Methods A group of international experts on FGIDs developed plausibility criteria that should be fulfilled by relevant pathophysiological mechanisms in FGIDs. Results Five criteria are proposed: (1) the presence of the abnormality in a subset of patients, (2) temporal association between proposed mechanism and symptom(s), (3) correlation between the level of impairment of the mechanism and symptom(s), (4) induction of the symptom(s) by provoking the pathophysiological abnormality in healthy subjects and (5) treatment response by a therapy specifically correcting the underlying disorder or congruent natural history of symptoms and dysfunction in the absence of specific therapy. Based on strength of evidence for these five criteria according to the Grading of Recommendations Assessment, Development and Evaluation system, a plausibility score can be calculated for each mechanism. Conclusion Evaluation of the strength of evidence for candidate pathophysiological abnormalities fulfilling these five plausibility criteria will help to identify the most relevant mechanisms to target for novel diagnostic approaches and for the development of new therapies.